[ad_1]
The event will be webcast on Thursday, September 23 at 11 a.m. ET
ROMAN Phase 3 Trial of Avasopasem Manganese, Galera’s Leading Candidate for SOM in Head and Neck Cancer Patients, Expected to Be Read in Q4 2021
MALVERN, Pa., September 14, 2021 (GLOBE NEWSWIRE) – Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on the development and commercialization of a pipeline of proprietary new therapeutics that have the potential to transform radiation therapy into cancer, today announced that the Company will host a Key Opinion Leader virtual event on radiation therapy-induced severe oral mucositis (SOM) in head and neck cancer patients on Thursday, September 23 at 11:00 a.m.ET.
Dr. Carryn Anderson, Clinical Associate Professor of Radiation Oncology at the University of Iowa, will present a review of the current clinical treatment paradigm for patients with locally advanced head and neck cancer, including the use of intensity modulated radiotherapy.
Dr. Anderson’s presentation will be followed by a video from a head and neck cancer survivor on his experience with SOM and a presentation from Galera President and CEO Mel Sorensen, MD, with an overview of the SOM market in patients with head and neck cancer. .
The live audio webcast of the event will be accessible from the News & Events section of the Investors page of Galera’s website at Investors.galeratx.com. Individuals can participate in an interactive question-and-answer session by submitting questions through the webcast platform.
An archived version of the webcast will be available for 30 days after the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiation therapy into cancer. Galera’s primary product candidate is avasopasem manganese (avasopasem, or GC4419), a small molecule selective dismutase mimic in late development to reduce the incidence and severity of severe oral mucositis (SOM) induced by radiation therapy in patients with head and neck cancer. Avasopasem is also in development for esophagitis induced by radiation therapy in patients with lung cancer. Avasopasem has received FDA designations for Fast Track and Breakthrough Therapy for the reduction of radiation therapy-induced SOM, with or without systemic therapy. Galera’s second dismutase mimetic product candidate, GC4711, is in clinical development to increase the anticancer efficacy of stereotaxic body radiation therapy in patients with non-small cell lung cancer and cancer locally advanced pancreas. Galera is headquartered in Malvern, Pennsylvania. For more information, please visit www.galeratx.com.
Investor contacts:
Christophe Degnan
Galera Therapeutics, Inc.
610-725-1500
[email protected]
William windham
Solebury Trout
646-378-2946
[email protected]
Media contact:
Zara Lockshin
Solebury Trout
646-378-2960
[email protected]
Source link
